Finni Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
ABA therapy practice management platform with instant insurance credentialing and billing; $3.32M from General Catalyst and YC with 50% MoM growth competing with CentralReach.
About
Finni Health is a healthcare technology platform providing business infrastructure for autism therapy providers — offering instant insurance credentialing, patient data management, billing automation, and payment processing that allows ABA (Applied Behavior Analysis) therapy practices to launch and scale without the administrative overhead that typically requires a full billing and operations team. Founded in 2023 and backed by $3.32 million led by General Catalyst and Y Combinator, Finni Health serves providers across five states and achieved $30,000 in monthly revenue with 50% month-over-month growth within seven months of launch.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.